Synthesis and Studies on Three-Compartment Flavone-Containing Combi-Molecules Designed to Target EGFR, DNA, and MEK

Chemical Biology and Drug Design

Volumn 77, Issue 5, 2011, Pages 309-318

  Larroque Lombard, Anne Laure ^a   Todorova, Margarita ^a   Qiyu, Qiu ^a   Jean Claude, Bertrand ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Combi molecules; DNA damaging agent; Epidermal growth factor receptor; MEK; Multitargeting; PD98059

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AL 232; AL 414; AMINOETHYLTRIAZENE; DNA; FD 105; FD 105AC; FLAVONE; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG ACETYLATION; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DNA; DNA DAMAGE; FEMALE; FLAVONOIDS; GENE EXPRESSION; HUMANS; MALE; MASS SPECTROMETRY; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIAZENES;

EID: 79954626774     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01098.x     Document Type: Article

References (32)

1. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res;284:31-53.
2. Dai Q., Ling Y.H., Lia M., Zou Y.Y., Kroog G., Iwata K.K., Perez-Soler R. (2005) Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res;11:1572-1578.
3. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y. et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol;21:2237-2246.
4. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H. et al. (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer;15:785-792.
5. Gaikwad A., Wolf J.K., Brown J., Ramondetta L.M., Smith J.A. (2009) In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Pract;15:35-44.
6. Konner J., Schilder R.J., DeRosa F.A., Gerst S.R., Tew W.P., Sabbatini P.J. et al. (2008) A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol;110:140-145.
7. Lacroix L., Pautier P., Duvillard P., Motte N., Saulnier P., Bidart J.M. et al. (2006) Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer;118:1068-1069.
8. Raju U., Nakata E., Mason K.A., Ang K.K., Milas L. (2003) Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res;63:3263-3267.
9. Banerjee R., Huang Y., McNamee J.P., Todorova M., Jean-Claude B.J. (2010) The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J Pharmacol Exp Ther;334:9-20.
10. Rachid Z., Brahimi F., Katsoulas A., Teoh N., Jean-Claude B.J. (2003) The combi-targeting concept: chemical dissection of the dual targeting properties of a series of 'combi-triazenes'. J Med Chem;46:4313-4321.
11. Matheson S.L., McNamee J.P., Wang T., Alaoui-Jamali M.A., Tari A.M., Jean-Claude B.J. (2004) The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther;311:1163-1170.
12. Brahimi F., Rachid Z., McNamee J.P., Alaoui-Jamali M.A., Tari A.M., Jean-Claude B.J. (2005) Mechanism of action of a novel 'combi-triazene' engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol;70:511-519.
13. Wynne P., Newton C., Ledermann J.A., Olaitan A., Mould T.A., Hartley J.A. (2007) Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer;97:927-933.
14. Kennedy R.D., D'Andrea A.D. (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol;24:3799-3808.
15. Matheson S., Qiu Q., Brahimi F., Dudouit F., Banerjee R., Rachid Z. et al. (2004) Combi-molecules: a global approach towards better chemoselectivity of cytotoxic agents and chemoresistance of refractory tumors. Bull Cancer;91:911-915.
16. Banerjee R. (2006) A novel small molecule-based multi-targeting approach for the selective therapy of epidermal growth factor receptor (EGFR)- or Her2-expressing carcinomas. Ph D dissertation, Faculty of Medicine.
17. Kharbanda S., Pandey P., Yamauchi T., Kumar S., Kaneki M., Kumar V. et al. (2000) Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol;20:4979-4989.
18. Upadhyay D., Bundesmann M., Panduri V., Correa-Meyer E., Kamp D.W. (2004) Fibroblast growth factor-10 attenuates H2O2-induced alveolar epithelial cell DNA damage: role of MAPK activation and DNA repair. Am J Respir Cell Mol Biol;31:107-113.
19. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem;270:27489-27494.
20. Dent P., Yacoub A., Fisher P.B., Hagan M.P., Grant S. (2003) MAPK pathways in radiation responses. Oncogene;22:5885-5896.
21. Yacoub A., McKinstry R., Hinman D., Chung T., Dent P., Hagan M.P. (2003) Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res;159:439-452.
22. Todorova M.I., Larroque A.L., Dauphin-Pierre S., Fang Y.Q., Jean-Claude B.J. (2010) Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther;9:869-882.
23. Larroque-Lombard A.L., Todorova M., Golabi N., Williams C., Jean-Claude B.J. (2010) Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5. J Med Chem;53:2104-2113.
24. Merayo N., Rachid Z., Qiu Q., Brahimi F., Jean-Claude B.J. (2006) The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs;17:165-171.
25. Cushman M., Nagarathnam D., Burg D.L., Geahlen R.L. (1991) Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues. J Med Chem;34:798-806.
26. Cushman M., Zhu H., Geahlen R.L., Kraker A.J. (1994) Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J Med Chem;37:3353-3362.
27. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D. et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst;82:1107-1112.
28. Olive P.L., Banath J.P. (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc;1:23-29.
29. Matheson S.L., McNamee J., Jean-Claude B.J. (2001) Design of a chimeric 3-methyl-1, 2, 3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther;296:832-840.
30. McNamee J.P., McLean J.R., Ferrarotto C.L., Bellier P.V. (2000) Comet assay: rapid processing of multiple samples. Mutat Res;466:63-69.
31. Hay M.P., Pruijn F.B., Gamage S.A., Liyanage H.D.S., Kovacs M.S., Patterson A.V. et al. (2004) DNA-targeted 1, 2, 4-benzotriazine 1, 4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. J Med Chem;47:475-488.
32. Guy J., Caron K., Dufresne S., Michnick S.W., Skene W.G., Keillor J.W. (2007) Convergent preparation and photophysical characterization of dimaleimide dansyl fluorogens: elucidation of the maleimide fluorescence quenching mechanism. J Am Chem Soc;129:11969-11977.